Engineering BCMA-CAR T cells to overcome CD19-negative relapse in B cell non-Hodgkin lymphomas

被引：0
|
作者：
Antonana-Vildosola, A. [1 ]
Perez-Amill, L. [1 ]
Sune, G. [1 ]
Castella, M. [1 ]
Najjar, A. [2 ]
Urbano, A. [1 ,3 ]
Martin-Antonio, B. [1 ,3 ]
机构：
[1] IDIBAPS, Barcelona, Spain
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Josep Carreras Leukemia Res Inst, Barcelona, Spain
来源：
HUMAN GENE THERAPY | 2019年 / 30卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P164
引用
收藏
页码：A67 / A68
页数：2
相关论文
共 50 条
  • [1] Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
    Rabilloud, Tracy
    Potier, Delphine
    Pankaew, Saran
    Nozais, Mathis
    Loosveld, Marie
    Payet-Bornet, Dominique
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [2] Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
    Tracy Rabilloud
    Delphine Potier
    Saran Pankaew
    Mathis Nozais
    Marie Loosveld
    Dominique Payet-Bornet
    Nature Communications, 12
  • [3] Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 29 - 33
  • [4] CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
    Shadman, Mazyar
    Gopal, Ajay K.
    Smith, Stephen D.
    Lynch, Ryan C.
    Ujjani, Chaitra S.
    Turtle, Cameron J.
    Greenbaum, Adam
    Redman, Mary
    Yeung, Cecilia
    Sersch, Martina
    Warren, Edus H.
    Maloney, David G.
    Till, Brian G.
    BLOOD, 2019, 134
  • [5] Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma
    Bachiller, Mireia
    Dobano-Lopez, Celia
    Rodriguez-Garcia, Alba
    Castellsague, Joan
    Gimenez-Alejandre, Marta
    Antonana-Vildosola, Asier
    Martin-Antonio, Beatriz
    Delgado, Julio
    Perez-Galan, Patricia
    Juan, Manel
    Urbano-Ispizua, Alvaro
    Guedan, Sonia
    BLOOD, 2022, 140 : 7386 - 7387
  • [6] Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel
    Ghilardi, Guido
    Lee, Yong Gu
    Porazzi, Patrizia
    Cohen, Ivan
    Paruzzo, Luca
    Ugwuanyi, Ositadimma H.
    Pajarillo, Raymone
    Zhang, Yunlin
    Guruprasad, Puneeth
    Patel, Ruchi P.
    Chong, Elise A.
    Nasta, Sunita Dwivedy
    Barta, Stefan K.
    Garfall, Alfred L.
    Landsburg, Daniel J.
    Sadigh, Sam
    Wasik, Mariusz
    Svoboda, Jakub
    Bhattacharyya, Siddharth
    Schuster, Stephen J.
    Ruella, Marco
    BLOOD, 2022, 140 : 7371 - 7373
  • [7] Chimeric T Cells for Therapy of CD30+Hodgkin and Non-Hodgkin Lymphomas
    Ramos, Carlos A.
    Ballard, Brandon
    Liu, Enli
    Dakhova, Olga
    Mei, Zhuyong
    Liu, Hao
    Grilley, Bambi
    Rooney, Cliona M.
    Gee, Adrian P.
    Chang, Bill H.
    Bollard, Catherine M.
    Brenner, Malcolm K.
    Dotti, Gianpietro
    Heslop, Helen E.
    Savoldo, Barbara
    BLOOD, 2015, 126 (23)
  • [8] Trivalent CAR T cells mitigate CD19-negative relapse and improve tumor control in primary pre-B cell acute lymphoblastic leukemia (B-ALL)
    Fousek, Kristen
    Watanabe, Junji
    An, Xingyue
    George, Ann
    Samaha, Heba
    Navai, Shoba
    Byrd, Tiara T.
    Kirzner, Jonathan
    Kim, Hye Na
    Jang, Albert
    Joseph, Sujith
    Baker, Matthew
    Hegde, Meenakshi
    Varadarajan, Navin
    Heisterkamp, Nora
    Abdel-Azim, Hisham
    Ahmed, Nabil
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [9] FACTORS PROMOTING CD19-NEGATIVE RELAPSES FOLLOWING CAR19T CELL THERAPY
    Dolnikov, A.
    Xu, N.
    Tse, B.
    Bishop, D.
    Gottlieb, D.
    Micklethwaite, K.
    O'Brien, T.
    CYTOTHERAPY, 2018, 20 (05) : S8 - S8
  • [10] The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas
    Xie, Y.
    He, T.
    Wu, F.
    Liu, G.
    Ding, Y.
    Lu, X.
    Song, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1599 - S1599
12345